Hyperlipidemia with Chronic Kidney Disease (CKD)
Conditions
Interventions
Patients are given atorvastatin 10 mg/day under dietary therapy based on the "
Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease"
and "
Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases"
. The dosage of atorvastatin can be increased up to 20mg/day when atorvastatin 10 mg/day fails to achieve the LDL-cholesterol target (less than 100mg/dL). When the target is not achieved with atorvast
. Antihyperlipidemic durugs except statins can be administered when dietary therapy alone fails to achieve the LDL-cholesterol target (less than 100mg/dL) after three months. When patients have alread
Sponsors
Kyoto University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) written informed consent, 2) age: from 40 to 74 years old, 3) either positive urine protein test or eGFR less than 60 ml/min/1.73m2 three months before enrollment, 4) eGFR less than 60 ml/min/1.73m2 at enrollment, 5) LDL-cholesterol of 140mg/dL or greater (LDL-cholesterol of 100mg/dL or greater if patients have already received an antihyperlipidemic drugs), 6) patient who are not treated with statins
Exclusion criteria
Exclusion criteria: 1) hepatic disease with decreased liver function, 2) familial hypercholesterolaemia, 3) eGFR less than 30 ml/min/1.73m2, 4) uncontrolled hypertension (systolic blood pressure of 180 mmHg or greater or diastolic blood pressure of 110 mmHg or greater), 5) poor controlled diabetics (HbA1c of 8.5% or greater), 6) nephrotic syndrome, 7) pregnancy or breast feeding, 8) known intolerance/adverse effects to atorvastatin, 9) patients who are inadequate to enter this study due to the other reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in eGFR | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) change in LDL-cholesterol, 2) change in triglyceride, 3) change in urinary albumin (mg/g*Cr), 4) cardiovascular event, 6) all-cause death, 8) safety parameters | — |
Countries
Japan
Contacts
Public ContactDepartment of EBM Research
Kyoto University Hospital iACT
Outcome results
None listed